These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 8690304)
1. [Nephrotoxicity and drug interaction of vancomycin (2)]. Toyoguchi T; Nakagawa Y Nihon Yakurigaku Zasshi; 1996 May; 107(5):225-35. PubMed ID: 8690304 [TBL] [Abstract][Full Text] [Related]
2. [Nephrotoxicity and drug interaction of vancomycin]. Toyoguchi T; Nakagawa Y; Watanabe H Nihon Yakurigaku Zasshi; 1996 Feb; 107(2):53-66. PubMed ID: 8721008 [TBL] [Abstract][Full Text] [Related]
3. Nephrotoxicity of vancomycin and drug interaction study with cilastatin in rabbits. Toyoguchi T; Takahashi S; Hosoya J; Nakagawa Y; Watanabe H Antimicrob Agents Chemother; 1997 Sep; 41(9):1985-90. PubMed ID: 9303398 [TBL] [Abstract][Full Text] [Related]
4. [Combined effect of vancomycin or teicoplanin plus a beta-lactam antibiotic in mouse infection models caused by beta-lactam antibiotec-induced vancomycin resistant MRSA (BIVR)]. Hatano K; Yokota Y; Hanaki H; Sunakawa K Kansenshogaku Zasshi; 2006 May; 80(3):243-50. PubMed ID: 16780131 [TBL] [Abstract][Full Text] [Related]
5. [Modification of vancomycin nephrotoxicity by other antibiotics in rats]. Itoh F; Sato K; Harauchi T; Hirata M; Mizushima Y Jpn J Antibiot; 1995 Mar; 48(3):380-8. PubMed ID: 7752451 [TBL] [Abstract][Full Text] [Related]
6. Effects of fosfomycin and imipenem/cilastatin on nephrotoxicity and renal excretion of vancomycin in rats. Nakamura T; Hashimoto Y; Kokuryo T; Inui KI Pharm Res; 1998 May; 15(5):734-8. PubMed ID: 9619782 [TBL] [Abstract][Full Text] [Related]
7. Effects of fosfomycin and imipenem-cilastatin on the nephrotoxicity of vancomycin and cisplatin in rats. Nakamura T; Kokuryo T; Hashimoto Y; Inui KI J Pharm Pharmacol; 1999 Feb; 51(2):227-32. PubMed ID: 10217324 [TBL] [Abstract][Full Text] [Related]
8. [Evaluation of the activity and effects of combinations of various antibacterial agents against methicillin-resistant Staphylococcus aureus in vitro]. Kouda M; Homma S; Udagawa I; Fukuhara J; Takeuchi M; Tamura K Jpn J Antibiot; 2000 Mar; 53(3):171-8. PubMed ID: 10834148 [TBL] [Abstract][Full Text] [Related]
9. Enhancement of antimicrobial effects of various antibiotics against methicillin-resistant Staphylococcus aureus (MRSA) by combination with fosfomycin. Nakazawa H; Kikuchi Y; Honda T; Isago T; Nozaki M J Infect Chemother; 2003 Dec; 9(4):304-9. PubMed ID: 14691650 [TBL] [Abstract][Full Text] [Related]
10. [Bacteriological evaluation of combined effects of vancomycin and beta-lactams. II. Results against gram-negative rods]. Deguchi K; Yokota N; Koguchi M; Suzuki Y; Fukayama S; Ishihara R; Oda S Jpn J Antibiot; 1993 Nov; 46(11):946-52. PubMed ID: 8309070 [TBL] [Abstract][Full Text] [Related]
11. [Bacteriological evaluation of combined effects of vancomycin and beta-lactams. I. Results against methicillin-resistant Staphylococcus aureus]. Deguchi K; Yokota N; Koguchi M; Suzuki Y; Fukayama S; Ishihara R; Oda S Jpn J Antibiot; 1993 Nov; 46(11):939-45. PubMed ID: 8309069 [TBL] [Abstract][Full Text] [Related]
12. [Effect of imipenem/cilastatin combined with vancomycin for MRSA infection]. Fukabori T; Mizobuchi K; Nakamura M; Takizawa H; Takashina R; Fujita Y Jpn J Antibiot; 1997 Apr; 50(4):299-305. PubMed ID: 9192247 [TBL] [Abstract][Full Text] [Related]
13. [In vitro effects of combinations of antibiotics against highly-fosfomycin-resistant, methicillin-resistant Staphylococcus aureus. With special reference to efficacies of combinations of imipenem/cilastatin and cephems]. Kouda M Jpn J Antibiot; 1993 Feb; 46(2):142-53. PubMed ID: 8331774 [TBL] [Abstract][Full Text] [Related]
14. [In vitro synergism of two-drug combinations among cefamandole, flomoxef and imipenem against MRSA]. Inoue M; Sakurai N; Matsui H; Tsunoda M; Okubo T Jpn J Antibiot; 1990 Feb; 43(2):233-8. PubMed ID: 2362351 [TBL] [Abstract][Full Text] [Related]
15. [The in vitro antibacterial activity of cefozopran against clinically isolated bacteria]. Higurashi Y; Okuzumi K; Yoneyama A; Nakahara K Jpn J Antibiot; 1997 Dec; 50(12):907-16. PubMed ID: 9545668 [TBL] [Abstract][Full Text] [Related]
16. [Clinical evaluation of imipenem/cilastatin sodium and fosfomycin as second-line combination chemotherapy in severe infections associated with hematologic disorders]. Tsuda S; Kuzuyama Y; Nakai H; Seriu T; Takashima T; Tanaka S; Horiike S; Taniwaki M; Misawa S; Kashima K Jpn J Antibiot; 1993 Feb; 46(2):171-83. PubMed ID: 8331778 [TBL] [Abstract][Full Text] [Related]
18. Time-Dependent Alterations of Vancomycin-Induced Nephrotoxicity in Mice. Takigawa M; Masutomi H; Kishimoto Y; Shimazaki Y; Hamano Y; Kondo Y; Arai T; Lee J; Ishii T; Mori Y; Ishigami A Biol Pharm Bull; 2017; 40(7):975-983. PubMed ID: 28674262 [TBL] [Abstract][Full Text] [Related]
19. [In vitro combination effect of vancomycin and carbapenems against carbapenem-resistant MRSA]. Sato S; Miura T; Kudo E; Kudo Y; Saitoh Y; Kimpara I; Tsujino M; Kudo H Jpn J Antibiot; 1997 Aug; 50(8):711-6. PubMed ID: 9339397 [TBL] [Abstract][Full Text] [Related]
20. Difference in nephrotoxicity of vancomycin administered once daily and twice daily in rats. Konishi H; Morita Y; Mizumura M; Iga I; Nagai K J Chemother; 2013 Oct; 25(5):273-8. PubMed ID: 24070134 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]